US Broker Ratings

Tenet Healthcare Corporation (THC) Stock Analysis: Exploring a 11.59% Potential Upside Amidst Strong Buy Ratings

Tenet Healthcare Corporation (THC), a stalwart in the healthcare sector, commands a significant presence in the United States’ medical care facilities industry with a robust market capitalization of $18.55 billion...

Alnylam Pharmaceuticals (ALNY): Investor Outlook Reveals Strong Revenue Growth and Promising Pipeline

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) stands as a formidable player in the biotechnology sector, with a market capitalization of $60.52 billion. The company’s innovative approach to therapeutics, centered on ribonucleic..

Becton, Dickinson and Company (BDX) Stock Analysis: Is a 4.44% Upside Worth Your Investment?

Becton, Dickinson and Company (NYSE: BDX) is a prominent player in the healthcare sector, specifically within the medical instruments and supplies industry. With a market capitalization of $55.59 billion, BDX..

Biogen Inc. (BIIB) Stock Analysis: Evaluating the Investment Potential Amidst a Complex Landscape

Biogen Inc. (NASDAQ: BIIB), a prominent player in the healthcare sector, specifically within the drug manufacturing industry, has long been recognized for its innovative contributions to treating neurological and neurodegenerative..

ResMed Inc. (RMD) Stock Analysis: 14% Potential Upside Beckons Investors

ResMed Inc. (NYSE: RMD), a prominent player in the Healthcare sector, is making waves across the Medical Instruments & Supplies industry with its innovative solutions for respiratory disorders. With a..

Quest Diagnostics (DGX) Investor Outlook: Discover the 8.11% Potential Upside in the Healthcare Diagnostics Leader

Quest Diagnostics Incorporated (NYSE: DGX) stands as a stalwart in the healthcare sector, specifically within the diagnostics and research industry. With a robust market capitalization of $20.41 billion, the company..

STERIS plc (STE) Stock Analysis: Exploring a 6.97% Potential Upside in the Healthcare Sector

Investors looking for opportunities in the healthcare sector might find STERIS plc (NYSE: STE) an intriguing option, especially given its potential upside of 6.97% based on current analyst ratings. STERIS,..

Royalty Pharma plc (RPRX) Stock Analysis: A Promising 15.74% Upside in the Biotech Sector

Royalty Pharma plc (NASDAQ: RPRX) stands out in the healthcare sector as a unique player with its focus on acquiring biopharmaceutical royalties. Based in New York, the company operates within..

IQVIA Holdings, Inc. (IQV) Stock Analysis: Exploring a 10.69% Upside Potential Driven by Healthcare Innovation

IQVIA Holdings, Inc. (NYSE: IQV) stands as a formidable player in the healthcare sector, particularly within the diagnostics and research industry. Headquartered in Durham, North Carolina, IQVIA leverages its global..

Edwards Lifesciences Corporation (EW) Stock Analysis: Exploring a Promising 10.69% Upside Potential

Edwards Lifesciences Corporation (NYSE: EW), a leader in the healthcare sector specializing in medical devices, has been gaining attention in the investment community. The company, with a market capitalization of..

Novo Nordisk A/S (NVO) Stock Analysis: Evaluating the 11.17% Potential Upside Amid Robust Growth

Novo Nordisk A/S (NVO), a titan in the global healthcare sector, commands a significant presence in the drug manufacturing industry, particularly focusing on diabetes and obesity care. Headquartered in Bagsvaerd,..

GSK plc (GSK) Stock Analysis: Evaluating the Healthcare Giant’s Performance and Potential Upside

GSK plc (GSK), a leading player in the healthcare sector, continues to capture investor attention with its robust market presence and strategic initiatives. With a market capitalization nearing $97.72 billion,..

Boston Scientific Corporation (BSX) Stock Analysis: A 29.7% Potential Upside Opportunity Amid Strong Revenue Growth

Boston Scientific Corporation (NYSE: BSX), a heavyweight in the healthcare sector with a commanding presence in the medical devices industry, presents a compelling investment opportunity for discerning investors. With a..

IDEXX Laboratories, Inc. (IDXX)

⚠️ No article content returned.

..

Zoetis Inc. (ZTS) Stock Analysis: Exploring a 39% Potential Upside in the Animal Health Leader

Zoetis Inc. (NYSE: ZTS), a prominent player in the healthcare sector, continues to capture investor interest with its leading position in the animal health industry. With a market capitalization of..

GE HealthCare Technologies Inc. (GEHC) Stock Analysis: Navigating Growth Prospects with a 3.86% Potential Upside

Investors looking at GE HealthCare Technologies Inc. (NYSE: GEHC) are observing a company that stands at the intersection of healthcare and technology, with a focus on advancing patient care through..

Vertex Pharmaceuticals (VRTX) Stock Analysis: A Robust Biotech with 6.98% Potential Upside and Strong Buy Ratings

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) continues to stand out in the biotechnology sector with a robust market capitalization of $116.78 billion. Known for its innovative treatments for cystic fibrosis (CF),..

Haleon plc (HLN) Stock Analysis: Exploring a 21.95% Potential Upside in the Healthcare Sector

Haleon plc (NYSE: HLN), a prominent player in the healthcare sector, specializes in the production and sale of consumer healthcare products. With a market capitalization of $42.39 billion, Haleon has..

Danaher Corporation (DHR) Stock Analysis: Solid Buy Ratings and 13% Potential Upside Highlight Growth Potential

Danaher Corporation (NYSE: DHR), a prominent player in the healthcare sector, particularly within the diagnostics and research industry, offers a compelling case for investors seeking growth opportunities. With a market..

Novartis AG (NVS) Stock Analysis: Evaluating Growth with a Promising 2.06% Upside

Novartis AG (NVS), a titan in the healthcare industry, continues to capture the attention of investors with its robust market presence and promising growth potential. Headquartered in Basel, Switzerland, Novartis..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds